Volition Validates Nu.Q NETs Biomarker In Sepsis; Stock Down

VolitionRx (VNRX) presented early-stage cancer detection data at ESMO MAP, showing 95% detection of stage I/II cancers using its Capture-Seq™ technology. The company targets a $36B market in early cancer detection and MRD, with plans to accelerate development and patent protection. Results showed no false positives in initial cohorts, with further studies underway.

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 13, 2026 /PRNewswire/ -- Volit

VolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of about $0.4 million, flat versus Q2 2025, and first-half 2026 revenue of $1.4 million, up 112% year over year. Operating expenses fell 32% and operating loss was $4.2 million. The company said it is discussing licensing deals, including a Sysmex collaboration, and expects a $5 million milestone from a Nu.Q Vet feline assay peer review.

Amgen (AMGN) shares rose 4% after reporting positive late-stage trial results for dazodalibep in treating systemic Sjögren’s disease, a condition with no approved therapy. The trial showed significant improvement in disease intensity. Citi noted positive results but awaits more details, maintaining a Neutral rating and $405 price target. AMGN is up 25% year-to-date.

Vertex Pharmaceuticals (VRTX) reported positive Phase 2b trial results for inaxaplin in treating APOL1-mediated kidney disease. The drug showed significant proteinuria reductions in two patient groups, with a favorable safety profile. Vertex expects interim Phase 2/3 trial results in early 2027, which could support U.S. approval. William Blair reiterated an Outperform rating, citing potential growth. VRTX shares rose 2.04% to $521.14.

Vertex Pharmaceuticals (VRTX) shares rose 3% after reporting positive trial results for inaxaplin in APOL1-mediated kidney disease (AMKD). The drug reduced protein leakage in urine by 42.7% for albumin and 44.7% for total protein in patients with modest proteinuria. Rival Maze Therapeutics (MAZE) shares jumped 25% on the read-through. Truist called the data a validation of APOL1 inhibition, estimating a market of over 100,000 patients and potential blockbuster sales for Maze's MZE829.